News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SkyePharma Inc. (SKYE) Announces Change of Marketing Partner


10/8/2007 8:51:50 AM

LONDON, UK - 8 October 2007 -- SkyePharma PLC (LSE: SKP) announces that the distribution and marketing rights for Solaraze® are being divested by Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) to Almirall together with a portfolio of other products which are principally sold by Shire in the UK, France, Germany, Italy, Spain and Ireland. Solaraze® (diclofenac), is a topical preparation for the treatment of actinic keratoses, which are common skin lesions on areas damaged extensively by sunlight. It is marketed in the US by Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals Inc. and has recently been launched in Australia by CSL Biotherapies under an agreement with Shire. SkyePharma receives a low teens royalty on relevant net sales; this is not affected by the proposed transfer from Shire to Almirall.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES